This study is looking at the safety and how well a new imaging agent, [18F]NOTA-ABY030, works in people with head and neck squamous cell carcinoma (HNSCC). This agent helps doctors see tumors better on PET/CT scans. You would first receive a dose of cetuximab (an EGFR inhibitor, a type of drug that targets cancer cells) through an IV, followed by an injection of [18F]NOTA-ABY030. Then, you would have PET/CT scans to see how the agent moves through your body and lights up any tumors. The main goal is to check for any side effects and how well your body tolerates [18F]NOTA-ABY030. This study is currently unclear on its recruitment status and plans to enroll 25 participants who are at least 18 years old and have been diagnosed with HNSCC, especially if their tumors are hard to identify with standard imaging.

Study design

This is a Phase I, single-institution, open-label study involving approximately 25 participants. It is not randomized, meaning all participants will receive the same interventions.

What's involved

You would receive an IV infusion of Cetuximab, a bolus injection of [18F]NOTA-ABY-030, and undergo PET/CT scans at specific times.

Compensation

Not stated in the trial record.

Follow-up

Your safety and tolerability will be assessed from the time of infusion up to 7 days post-infusion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.